Antireumatikus

Antireumatikus is a term used in several languages to describe substances, therapies, or approaches that counteract rheumatic diseases. In medical contexts it most often refers to treatments intended to reduce inflammation, relieve pain, and slow the progression of autoimmune or inflammatory rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis, lupus, and other connective tissue diseases. The word can function as an adjective (antireumatikus drug) or as a general descriptor for antirheumatic care.

In pharmacology, antireumatikus therapies encompass a range of drug classes. Nonsteroidal anti-inflammatory drugs (NSAIDs) provide symptomatic relief from pain and inflammation. Corticosteroids may be used for short-term control of disease flares. Disease-modifying antirheumatic drugs (DMARDs) aim to slow or halt disease progression; traditional DMARDs include methotrexate, sulfasalazine, and hydroxychloroquine. Biologic DMARDs and targeted synthetic DMARDs, such as TNF inhibitors and JAK inhibitors, are employed for more severe or resistant disease. Nonpharmacologic measures—physical therapy, regular exercise, occupational therapy, and lifestyle adjustments—are important components of antireumatikus care to maintain joint function and overall well-being.

The exact usage of the term varies by language and country, but it generally denotes concepts related to anti-rheumatic therapy. As with all medical treatments, antireumatikus approaches require professional evaluation and monitoring to balance benefits with potential risks.